Lv8
7620 积分 2023-02-21 加入
Abstract 5461: BG-C477, a novel topoisomerase 1 inhibitor-based ADC, exhibits antitumor activity in carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)-expressing preclinical models
2天前
已采纳
Abstract CT039: Results of a first-in-human phase 1 trial of anchored IL-12 drug conjugate (ANK-101)
2天前
已采纳
Abstract 432: Mechanisms of acquired resistance to ARV-471, a novel PROTAC® estrogen receptor degrader
1个月前
已采纳
Abstract 5001: Open-label, non-randomized, exploratory pre-operative window-of-opportunity trial to investigate the pharmacokinetics and pharmacodynamics of the smac mimetic Debio 1143 in patients with resectable squamous cell carcinoma of the head and neck
1个月前
已采纳
Data from Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-like Responses Against CD30<sup>+</sup> Malignancies
1个月前
已采纳
Abstract 2826: Celastrol-Cu nanoparticles induce self-amplified cuproptosis augmented cancer immunotherapy
1个月前
已采纳
Abstract CT275: Phase 1 clinical update of allogeneic invariant natural killer T cells (iNKTs), agenT-797, alone or in combination with pembrolizumab or nivolumab in patients with advanced solid tumors
1个月前
已采纳
Abstract A081: Resistance Mechanisms to Monotherapy RAS(ON) Multi-Selective Inhibitor Daraxonrasib (RMC-6236) in RAS Mutant PDAC Inform Therapeutic Combination Strategies
1个月前
已采纳
Abstract PS4-04-30: Discovery of NKT5097: a first-in-class, highly potent and selective, orally bioavailable CDK2/4 dual degrader for cancer therapy
2个月前
已采纳
AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family
2个月前
已采纳
皖公网安备34019202002308
